News - Pharmaceuticals
First national action plan for rare diseases

The Morrison Government will provide up to $3.3 million for activities to implement the first National Strategic Action Plan for Rare Diseases, which was launched yesterday ahead of Rare Disease Day (February 29, 2020) .
The Action Plan will increase awareness and promote earlier, more accurate diagnosis and treatment for around two million Australians suffering from rare diseases.
Rare diseases are having a major impact on individuals and families across Australia. They cause great uncertainty, frustration and fear, raising a myriad of questions, with few answers.
While each rare disease affects less than five in every 10,000 people, there are more than 7,000 currently known rare diseases.
Approximately 80 per cent of rare diseases are of genetic origin. Others include rare cancers, infections and autoimmune disorders.
The Action Plan is comprised of three pillars:
- Awareness and education.
- Care and support.
- Research and data.
Each pillar has key priorities for action, including prevention, early detection and screening, accurate and fast diagnosis, and access to the right treatment.
The Government provided $170,000 to Rare Voices Australia to develop the Action Plan, including consultation with stakeholders and people living with rare diseases, their families and carers.
The Government will provide up to $3.3 million for activities to implement the Action Plan, including activities to improve the medical profession’s knowledge and awareness of rare diseases.
Rare Voices Australia will receive up to $1 million over three years, from next financial year, to continue its work as the peak body for this issue.
We will also be calling for organisations to develop and deliver new education resources to health professionals, and to provide new support for people living with a rare disease, with a total funding of up to $2.3 million.
You may also like Access to genomic testing to reduce the exhausting journey of rare disease diagnosis in children
Digital & Innovation
Health sector faces new privacy obligations
Healthcare organisations must update their privacy policies by 10 December if they use artificial intelligence (AI) or a computer program […]
MoreNews - Pharmaceuticals
TGA approves new antibiotic but AMR blind spot remains a critical concern
The Therapeutic Goods Administration (TGA) has approved a new antibiotic for the treatment of carbapenem-resistant Gram-negative bacterial infections. Developed by […]
MoreNews - MedTech & Diagnostics
BCAL Diagnostics rejects merger speculation
ASX-listed BCAL Diagnostics has moved to quash speculation of a potential three-way merger involving Genetic Signatures and Microba Life Sciences, […]
MoreNews - Pharmaceuticals
Australia backs infectious disease innovation as US funding faces more cuts
Biointelect Venturer, a national incubator supporting infectious disease innovation, will open its second funding round later this month, with AUD […]
More